Table III.
Clinical improvements throughout the 156 weeks of treatment
| Response endpoints | Week 0 (n = 70)b | Week 16 (n = 70)b | Week 32 (n = 57)b | Week 52 (n = 50)b | Week 104 (n = 34)b | Week 156 (n = 27)b |
|---|---|---|---|---|---|---|
| EASI, mean ± (SD)a | 27.9 ± (5.5) | 6.7 ± (7.1) | 2.2 ± (2.8) | 0.8 ± (2.1) | 1.1 ± (2.3) | 0.8 ± (2.3) |
| NRS-itch, mean±(SD)a | 8.1 ± (1.4) | 2.5 ± (2.1) | 0.9 ± (1.5) | 0.5 ± (1.2) | 0.9 ± (1.8) | 0.6 ± (1.8) |
| DLQI, mean ± (SD)a | 15.7 ± (6) | 3.9 ± (4) | 0.9 ± (2.2) | 0.6 ± (2.0) | 0.8 ± (2.2) | 0.4 ± (1.0) |
| EASI75 n (%) | 34 (48.6) | 43 (75.4) | 42 (84) | 24 (70.6) | 23 (85.2) | |
| EASI90 n (%) | 25 (35.7) | 27 (47.4) | 41 (82) | 23 (67.6) | 23 (85.2) |
Clinical response was assessed at 16, 32, 52, 104, and 156 weeks during treatment using the following tools: Eczema Area and Severity Index (EASI), ranging from 0 to 72 points; itch Numeric Rating Scale (NRS), ranging from 0 to 10 points; Dermatology Life Quality Index (DLQI), ranging from 0 to 30 points.
a
p < 0.001 vs baseline (paired t-test; see Methods).
b
Reduction in the number of patients at each follow-up visit was due to the fact that patients started treatment at different times and that not all patients had completed 156 weeks of treatment by the time of the present study.
SD: standard deviation.